Evolus EOLS Jeuveau — Total net revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Evolus in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Evolus’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Evolus's jeuveau — total net revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Evolus's jeuveau — total net revenues?
- Evolus (EOLS) reported jeuveau — total net revenues of $66.02M in Q1 2026.
- How has Evolus's jeuveau — total net revenues changed year-over-year?
- Evolus's jeuveau — total net revenues decreased by 3.0% year-over-year, from $68.07M to $66.02M.
- What is the long-term trend for Evolus's jeuveau — total net revenues?
- Over 2 years (2023 to 2025), Evolus's jeuveau — total net revenues has grown at a 16.8% compound annual growth rate (CAGR), from $199.72M to $272.32M.
- What does jeuveau — total net revenues mean?
- This metric represents the total net revenue generated from the sale of the company's primary botulinum toxin product within the aesthetic market. It reflects the core commercial performance and market adoption of the product after accounting for returns, allowances, and discounts. This figure serves as a key indicator of the company's ability to capture market share in the self-pay aesthetic sector.